Alterity Therapeutics (ATHE) vs BriaCell Therapeutics (BCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alterity Therapeutics (ATHE) has outperformed BriaCell Therapeutics (BCTX) over the past year, losing 56.7% versus a loss of 61.7%. Over five years, ATHE leads with a -85.4% price change compared with -97.0% for BCTX. Alterity Therapeutics is the larger company by market cap ($29.0 million vs $26.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATHE | BCTX |
|---|---|---|
| Share price | $1.52 | $3.06 |
| Market cap | $29.02M | $26.72M |
| 1-day change | -8.16% | -3.32% |
| YTD return | -50.65% | -56.96% |
| 1-year return | -56.70% | -61.75% |
| 5-year return | -85.38% | -97.00% |
| EPS (TTM) | $-0.90 | $-6.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-34.90M |
| 52-week high | $5.89 | $13.09 |
| 52-week low | $1.52 | $2.60 |
| Distance from 52-week high | -74.19% | -76.62% |
| Analyst consensus | none | — |
| Avg. price target upside | +771.71% | — |
| Average volume | 89.63K | 250.81K |
| Shares outstanding | 19.09M | 8.73M |
| Employees | 11 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Alterity Therapeutics
ATHE stock →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
ATHE vs BCTX FAQ
Which is bigger, Alterity Therapeutics or BriaCell Therapeutics?
Alterity Therapeutics (ATHE) is larger, with a market capitalization of $29.02M compared with $26.72M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, ATHE or BCTX?
ATHE returned -56.70% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.
Are Alterity Therapeutics and BriaCell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.